Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN5X17)

• Drug Name: BZ3 Drug Info
• Synonyms: 5-METHOXYINDOLE; 1006-94-6; 5-Methoxy-1H-indole; 1H-Indole, 5-methoxy-; Femedol; 5-Methoxy indole; Indole, 5-methoxy-; Methoxy-5 indole; Indol-5-yl methyl ether; UNII-DQM3AS43PQ; Methoxy-5 indole [French]; 5-Methoxyindole, 99%; EINECS 213-745-3; DQM3AS43PQ; NSC 521752; CHEMBL280311; DWAQDRSOVMLGRQ-UHFFFAOYSA-N; MFCD00005674; 916979-77-6; BZ3; 5Methoxyindole; 5-methoxyindol; 5-methoxy-indole; 3img; 3imc; PubChem7432; 1,3-dihydro-5-methyl-2H-Indol-2-one; ACMC-1BMAQ; 5-(methyloxy)-1H-indole; AC1Q4F1F; AC1L22NW; SCHEMBL74720; KSC177G3N; WLN: T

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 13872
  CAS Number: CAS 1006-94-6
  TTD Drug ID: DMN5X17

Molecule-Related Drug Atlas

Drug(s) Targeting Poly [ADP-ribose] polymerase 1 (PARP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide	DMUPE07	Acne vulgaris	ED80	Approved	[3]
KU-0058948	DMSA4HZ	Ovarian cancer	2C73	Approved	[4]
Niraparib Tosylate	DMLPSWQ	Fallopian tube cancer	2C74	Approved	[5]
CC-486	DMTNQB0	Acute myeloid leukaemia	2A60	Phase 3	[6]
Nicaraven	DMFBNA3	Cerebrovascular disease	8B2Z	Phase 3	[7]
PMID27841036-Compound-37	DM0OVZ2	Ovarian cancer	2C73	Phase 2	[8]
Stenoparib	DMKVBL8	Ovarian cancer	2C73	Phase 2	[9]
AG140699	DMA9FKY	Melanoma	2C30	Phase 2	[10]
AZD5305	DMW9R1C	Prostate cancer	2C82.0	Phase 2	[11]
AMXI 5001	DMR9H6B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[12]

Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[15]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[17]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[17]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[18]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[19]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[20]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[21]

Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[22]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[23]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[24]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[25]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[26]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[27]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[28]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[17]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[29]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[30]

Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[31]
Dapsone	DM4LT8A	Acne vulgaris	ED80	Approved	[17]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[16]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[28]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[32]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[17]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[33]
Fluconazole	DMOWZ6B	Cryptococcal meningitis		Approved	[16]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase 1 (PARP1)	TTVDSZ0	PARP1_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Gene/Protein Processing	[2]

References

• [1] Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8.
• [2] Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008 Jul;36(7):1322-31.
• [3] beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
• [4] Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
• [7] Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
• [8] PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
• [9] Clinical pipeline report, company report or official report of Allarity Therapeutics.
• [10] Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
• [11] Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
• [12] AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
• [13] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
• [14] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [15] Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
• [16] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [17] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [18] Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
• [19] Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
• [20] Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
• [21] Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
• [22] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [23] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [24] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [25] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [26] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [27] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [28] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [29] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [30] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [31] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [32] Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
• [33] The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.